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Background
Oral deferiprone was suggested to be more effective than subcutaneous desferrioxamine for
removing heart iron. Oral once-daily chelator deferasirox has recently been made commercially
available but its long-term efficacy on cardiac iron and function has not yet been established.
Our study aimed to compare the effectiveness of deferasirox, deferiprone and desferrioxamine
on myocardial and liver iron concentrations and bi-ventricular function in thalassemia major
patients by means of quantitative magnetic resonance imaging.
Design and Methods
From the first 550 thalassemia subjects enrolled in the Myocardial Iron Overload in
Thalassemia network, we retrospectively selected thalassemia major patients who had been
receiving one chelator alone for longer than one year. We identified three groups of patients: 24
treated with deferasirox, 42 treated with deferiprone and 89 treated with desferrioxamine.
Myocardial iron concentrations were measured by T2* multislice multiecho technique.
Biventricular function parameters were quantitatively evaluated by cine images. Liver iron con-
centrations were measured by T2* multiecho technique. 
Results
The global heart T2* value was significantly higher in the deferiprone (34±11ms) than in the
deferasirox (21±12 ms) and the desferrioxamine groups (27±11 ms) (P=0.0001). We found high-
er left ventricular ejection fractions in the deferiprone and the desferrioxamine versus the
deferasirox group (P=0.010). Liver iron concentration, measured as T2* signal, was significantly
lower in the desferrioxamine versus the deferiprone and the deferasirox group (P=0.004).
Conclusions
The cohort of patients treated with oral deferiprone showed less myocardial iron burden and
better global systolic ventricular function compared to the patients treated with oral deferasirox
or subcutaneous desferrioxamine. 
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Introduction
Heart failure mainly related to iron-induced toxicity
remains the leading cause of morbidity and mortality in
thalassemia major (TM) patients, although life-expectancy
in this population has improved in the last years.1,2
Therefore, chelation strategies to prevent heart disease
should have the highest priority.2
The oral chelating agent deferiprone was proved to be
more effective than subcutaneous desferrioxamine for
removing heart iron, measured by T2* MRI,3-5 and in
improving survival.2,6-9 Also the novel oral once-daily iron
chelator deferasirox, which should be able to improve com-
pliance, is now commercially available. To date, no prospec-
tive randomized studies have been published on the cardiac
efficacy of deferasirox. Some recent reports have suggested
that deferasirox may be effective in increasing heart T2* sig-
nal in thalassemia major patients.10-12 However, these stud-
ies did not compare all three chelators (deferasirox,
deferiprone and desferrioxamine) together. Conversely, a
recently published observational study comparing four
chelator regimens did not show a statistically significant
improvement in cardiac iron load in thalassemia major
patients treated with deferasirox,13 although this study
suffered from a variable time period between MRI scans,
and it did not take into account compliance or chelator
dosage. 
Magnetic resonance imaging (MRI) by the T2* tech-
nique allows highly reproducible and non-invasive quan-
tifications of myocardial14-16 and liver 14,17,18 iron burden in
the clinical arena, and has been contributing to improved
survival in thalassemia patients.19 Moreover, MRI is the
gold standard for quantifying biventricular function
parameters.20
Therefore, the aim of our study was to compare retro-
spectively in a large cohort of patients with thalassemia
major the effectiveness of the three available iron chela-
tors (deferasirox, deferiprone and desferrioxamine) on
myocardial and liver iron concentrations and on biventric-
ular function measured by quantitative MRI.
Design and Methods
Study population
The MIOT (Myocardial Iron Overload in Thalassemia) project
is a network involving six Italian Cardiac Magnetic Resonance
(CMR) sites and 57 Italian thalassemia centers where CMR proce-
dure is performed using homogeneous, standard and validated
procedures.21 All centers are linked by a web-based network, con-
figured to collect and share patients’ data.22 From the 550 tha-
lassemia patients enrolled in the MIOT network, we retrospec-
tively selected the 115 thalassemia major patients (73 males, age 9-
56 years, mean age 31±9 years) receiving one chelator alone for
longer than one year. All patients had been regularly transfused
since early childhood, starting chelation treatment with desfer-
rioxamine in the mid to late 1970s.
We identified three groups of patients: 24 patients treated with
deferasirox, 42 patients treated with deferiprone and 89 patients
treated with desferrioxamine. The mean administered dosages of
the three chelators were: 1) deferasirox 26±6.3 mg/kg body weight
per day (range 18-40 mg/kg body weight per day); 2) deferiprone
72±10 mg/kg body weight (range 50-86 mg/kg body weight per
day), divided into three doses per day; 3) desferrioxamine 30±9
mg/kg body weight/infusion via subcutaneous route on 3-7 days
per week (range 24-52 mg/kg body weight). 
The study complied with the Declaration of Helsinki. All
patients gave written informed consent to the protocol. The insti-
tutional review board approved this study. 
Magnetic resonance imaging
At all six sites, CMR exams were performed by a 1.5 T scanner
(GE Signa/Excite HD, Milwaukee, WI, USA) using previously
reported cardiac-gated techniques.4,15,23
In brief, for the MIO measurements, a multislice multiecho T2*
approach was used. Three parallel short-axis views (basal, medi-
um and apical) of the left ventricle (LV) were acquired at nine
increasing echo times (TE) (2.2–20.3 ms) in a single end-expiratory
breath-hold. The transferability of multislice multiecho T2* within
the MIOT network has been previously validated.21 For the meas-
urement of liver iron overload, a T2* single breath-hold, 9-echo
sequence (TEs 2.0–21 ms) of a transaxial slice was acquired.17
T2* image analysis was performed using a custom-written, pre-
viously validated software program (HIPPO MIOT®, IFC-CNR).
The software was able to map the myocardial T2* distribution
into a 16-segment LV model according to the American Heart
Association (AHA)/American College of Cardiology (ACC) stan-
dardized myocardial segmentation.24 The intra-observer, inter-
observer and inter-study variability of the proposed methodology
had been previously assessed.15 The global T2* value was obtained
by averaging segmental T2* values, and the T2* value in the mid-
ventricular segment was obtained by averaging segmental T2* val-
ues in the mid-anterior septum and the mid-inferior septum. As
previously shown,23,25 the developed procedure was able to correct
for cardiac/visceral geometrical and susceptibility artefacts. T2*
greater than 20 ms was considered as a conservative normal value
for all 16 segments, for the mid-ventricular septum and for the
entire heart.14,23
For the liver, the decay curve was extracted from a large region
of interest of standard dimensions, chosen from a homogeneous
area of liver parenchyma without blood vessels, and the value of
T2* was calculated by fitting the decay curve model with a single
exponential with a constant offset.16,17 We expressed the liver iron
concentration (LIC) also in mg/g dry weight. We used the conver-
sion from T2* to LIC, by using the formula, 0.202+25.4/T2* adapt-
ed from Wood et al.26
Steady-state free procession cine images were acquired during
8-second breath-holds in sequential 8-mm short-axis slices from
the atrio-ventricular ring to the apex to assess biventricular func-
tion parameters quantitatively in a standard way,20 using MASS®
software (Medis, Leiden, The Netherlands). 
Statistical analysis
All data were analyzed using the SPSS version 12.0 statistical
package. Summary data are presented as mean ± standard devia-
tion. Comparisons among groups were made by one-way
ANOVA for continuous values with normal distribution and
Kruskal-Wallis test for continuous values with non-normal distri-
bution (i.e. T2* data). Multiple comparisons were made by t test
or Mann-Whitney test and P values were modified according to
the Bonferroni correction. The c2 test was used for non-continuous
variables. Spearman’s test was used for correlation analysis. A
two-tailed probability value of 0.05 was considered statistically
significant.
Results
There was no difference between the three groups in
gender, pre-transfusional Hb levels, age at the first chela-
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tion, compliance to the active chelation treatment or pre-
vious intensive chelation therapies (24 h infusions of des-
ferrioxamine through portacaths and/or combination ther-
apy with desferrioxamine and deferiprone). The
deferasirox group was significantly younger than the
deferiprone and the desferrioxamine groups (P=0.0001).
Desferrioxamine treatment had been started significantly
earlier (24±10 years, range 1-47 years) than the
deferiprone treatment (4±4 years, range 1-18 years;
P<0.0001) and the deferasirox treatment (2±1 years, range
1-5 years; P<0.0001). The basal mean serum ferritin levels
in the 12 months before starting the active treatment at
the time of MRI were significantly higher in the
deferasirox group versus the desferrioxamine group
(2,491±2,072 vs. 957±1,073; P=0.0003) while they were
comparable with the deferiprone group (1,665±2,028;
P=0.1); there was no significant difference in basal mean
serum ferritin levels between the deferiprone group and
the desferrioxamine group (P=0.1). The majority of the
study patients were naïve to T2* MRI (85%). The 17
patients with a previous T2* MRI scan were homogenous-
ly distributed in the 3 groups (deferiprone 6 of 42 patients,
desferrioxamine 7 of 89 patients, deferasirox 4 of 24
patients; P=NS). Out of the 17 patients with a previous
T2* MRI, only 2 patients changed the chelation therapy
between the two MRI scans. The 2 patients were
switched from desferrioxamine to deferiprone due to an
unsatisfactory compliance to the subcutaneous desferriox-
amine administration. However, in both patients the
study MRI and the previous MRI showed normal global
heart T2* values. Baseline clinical findings for the three
groups are reported in Table 1.
Global and mid-ventricular septum heart T2* values
were significantly higher in the deferiprone-group than
the deferasirox and the desferrioxamine groups (P=0.0001)
(Figure 1). Moreover, the number of segments with nor-
mal T2* values was significantly higher in the deferiprone
and the desferrioxamine groups than in the deferasirox
group (P=0.0001). 
We did not find a significant correlation between the log
global heart T2* and the iron chelator dosage (deferiprone
r=-0.13 P=0.45; desferrioxamine r=-0.19 P=0.09;
deferasirox r=-0.098 P=0.762). The correlation between
the log global heart T2* and the LIC (mg/g dw) was not
significant in the deferiprone and deferasirox groups
(r=0.279  P=0.07, r=-0.33 P=0.11, respectively). We found
a mild and significant correlation between the log global
heart T2* and the LIC (mg/g dw) in the desferrioxamine
group (r=-0.354 P=0.001).
The deferiprone group showed significantly higher left
ventricular ejection fraction than the desferrioxamine and
deferasirox groups (P=0.010) (Figure 2). Similarly, the right
ventricular ejection fraction was higher in the deferiprone
group than in the desferrioxamine and deferasirox groups
(P=0.042). Although none of the patients suffered from
decompensated heart failure (HF) at the time of the scan,
5 patients showed the left ventricular ejection fraction
(LVEF) less than 50% (3 patients treated with desferriox-
amine and 2 patients treated with deferasirox), 5 patients
treated with desferrioxamine showed the right ventricular
ejection fraction (RVEF) less than 45%, and one patient
treated with desferrioxamine showed the LVEF less than
50% and the RVEF less than 45%. There was no statisti-
cally significant difference in left and right end-diastolic
volume indices and in left ventricular mass index between
groups. 
Liver iron concentrations (mg/g dw) were significantly
lower in the desferrioxamine group than in the
deferiprone and deferasirox groups (P=0.004) (Figure 3).
Mean serum ferritin levels in the last year of the active
treatment were significantly higher in the deferasirox-
group (2,516±2,106 ng/mL) versus the desferrioxamine-
group (987±915 ng/mL) (P=0.001) while they were com-
parable with the deferiprone group (1,493±1,651 ng/ml)
(P=NS) (Figure 4). Comparisons between heart and liver
iron and biventricular function parameters in the different
groups by MRI are reported in Table 2. 
Discussion
The availability of three iron chelators allows physicians
to tailor the chelation regimens to the needs of different
patients. Therefore, it is important to establish whether
these drugs have a different effect on different organs.
Although surrogate markers such as serum ferritin levels
and liver iron concentration have been shown to be prog-
nostic indicators in most of the thalassemia patients, they
do not always correlate with the cardiac iron burden and
function.13,4,25 MRI, a technique that provides highly repro-
ducible measurements of myocardial14-16 and liver iron bur-
den,17,18 and biventricular function parameters,20 is ideally
suited for comparing different chelation treatments in tha-
lassemia major patients.3-5 In particular, the method used
in this study to quantify the myocardial iron burden
assessed not only the T2* in the mid-ventricular septum,
but also the global heart iron and the number of segments
with normal T2* value. This assessment is not usually
referred to in studies on thalassemia patients and it can be
advantageous in that the distribution of iron in the heart is
heterogeneous.15,27
Our large multicenter observational study showed that
thalassemia major patients treated with deferiprone alone
had significantly less global and segmental myocardial
Cardiac iron in thalassemia with DFX, DFP and DFO
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Table 1. Clinically relevant findings in the three groups of chelation treat-
ment.
                                     Deferiprone   Desferrioxamine   Deferasirox       P
                                          group                group               group 
                                         (n=42)               (n=89)             (n = 24)
Age (years)                              31±9                     33±8                 26±7 (*)        0.001
M/F                                             20/22                      42/47                     11/13              NS
Pre-transfusion Hb             9.5±0.7                 9.6±0.6                 9.7±0.5           NS
(g/dl)                                              
Chelation starting age          8±10                      5±3                       5±5               NS
(years)                                           
Active treatment duration    4±4                     24±10                     2±1           0.0001 
(years)                                           
Excellent /good                         93                           93                          92                NS
compliance (%)                          
Previous 24 h DFO                    2                             1                             0                 NS
portacaths (%)                            
Previous combination             12                            6                             8                 NS
therapy (%)                                  
Previous intensive                   14                            7                             8                 NS
chelation therapy (%)               
NS: not significant.
iron burden and significantly better global systolic ventric-
ular function than patients treated with desferrioxamine
and deferasirox alone for a minimum of 12 months at
comparable levels of compliance (Figures 1 and 2).
Moreover, none of the patients treated with deferiprone
showed LVEF less than 50% and/or RVEF less than 45%
that can be considered indicative of heart failure in tha-
lassemia major patients.28 Conversely, the desferrioxamine
group showed less liver iron burden than the patients
treated with the other two chelators (Figure 3).
There was no significant difference in age at which
chelation was started and the exposure to intensive chela-
tion therapy among groups. All three groups showed high
and comparable levels of compliance. In our outpatients
population, compliance data were collected by the inves-
tigators of each thalassemia center and seem to be concor-
dant with the levels of liver and cardiac iron burden. This
datum could be justified by the organization of the nation-
al health system, by the free availability of MRI, and by
the support of the voluntary associations and of the fami-
ly. As expected, in our study population, desferrioxamine,
which has been on the market for the past thirty years,
had been started significantly earlier than the deferiprone
and the deferasirox treatments. 
Deferiprone and deferasirox groups showed comparable
basal mean serum ferritin levels. Thus, we cannot attribute
the greater efficacy of deferiprone in removing/preventing
cardiac iron to a lower baseline iron burden. 
Previous knowledge of cardiac iron burden seems not to
have introduced any bias in our study population. In fact,
a high percentage of the patients (85%) were naïve to T2*
MRI and patients with a previous T2* MRI were homoge-
nously distributed across the three groups. Moreover, of
the patients with a previous T2* MRI, only 2 patients had
changed the chelation therapy between the two MRI
scans and these 2 patients had normal global heart T2* val-
ues in both scans; the chelation therapy had been changed
due to patient compliance. 
Previous retrospective3,4 and prospective randomized
clinical trials5 have shown deferiprone to be more effective
than subcutaneous desferrioxamine in preventing and
removing myocardial iron burden and improving sur-
vival.2,6-9
In one recently published preliminary prospective
study,10 deferasirox when given at a mean dosage of
32.6mg/kg/day for one year in thalassemia major patients
with cardiac iron and normal/borderline left ventricular
ejection fraction, led to negative cardiac and liver iron bal-
ance and maintained ejection fraction. One observational
prospective, open-label, single-arm study11 suggested that
deferasirox monotherapy, administered at the dose of 30-
40 mg/kg/day for 18 months, maintained unchanged the
ejection fraction in patients with normal/borderline left
ventricular ejection fraction and was effective in patients
with mild-to-moderate iron stores in removing cardiac
iron; however, this monotherapy failed in patients with
severe hepatic iron burdens. Another single-arm observa-
tional study showed significant improvement in cardiac
T2* in heavily iron loaded thalassemia major patients
receiving iron deferasirox over an 18-month period.12 All
these studies were limited by the short period of treat-
ment evaluation. 
On the contrary, a recently published non-prospective
and non-randomized observational study from Greece
showed no statistically significant improvement in cardiac
iron load in thalassemia major patients on deferasirox at
any level of cardiac iron loading.13
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Figure 1. Global heart T2* and the T2* in the mid-ventricular sep-
tum in the groups treated with deferiprone, desferrioxamine and
deferasirox. There were significant differences among groups
(P=0.0001). Post hoc analysis showed significantly higher global
heart T2* and T2* in the mid-ventricular septum in the group treat-
ed with deferiprone versus the group treated with desferrioxamine
and deferasirox. Each box shows the median, quartiles, and extreme
values within the category.
Figure 2. Left ventricular ejection fraction in the groups treated with
deferiprone, desferrioxamine and deferasirox. There were significant
differences among groups (P=0.010). Post hoc analysis showed a
significantly higher left ventricular ejection fraction in the group
treated with deferiprone versus the group treated with deferasirox.
Each box shows the median, quartiles, and extreme values within
the category.
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In the three above mentioned prospective studies,10-12 as
opposed to the Greek13 and to our study, deferasirox was
given at higher doses (30 mg/kg/day with the possibility
of increasing the dose to over 40 mg), possibly explaining
the difference in results obtained. Moreover, out of the 24
patients in the deferasirox group, 13 patients had partici-
pated in clinical trials in the 12 months before the MRI. In
this subgroup, the mean dosage of the deferasirox in the
last 12 months before the scan was 30±7 mg/kg/day
(range 20-40 mg/kg/day) and we cannot exclude a previ-
ous underdosing. Anyway, in our study population, we
did not find significant correlation between the global
heart T2* and the drug dosage of the three iron chelators.
With respect to the liver, in contrast to the lower
myocardial iron overload in the deferiprone group, the
desferrioxamine group showed significantly higher liver
iron T2* values than the other two groups, and significant-
ly lower mean serum ferritin levels in the last year of treat-
ment than the deferasirox group. The significantly lower
mean ferritin levels and LIC in the desferrioxamine group
versus the deferasirox group could be influenced by the sig-
nificantly lower basal serum ferritin levels in the desfer-
rioxamine group versus the deferasirox group. The ability
of desferrioxamine to significantly reduce body iron bur-
den has been repeatedly demonstrated.29 However, in all
the series reported, 65% of the patients treated with des-
ferrioxamine alone were found to have a T2* in the mid-
ventricular septum less than 20 ms and, therefore, less
than an optimal target.30 These findings confirm a possible
important difference in drug action: deferiprone seems to
be a better agent for removing/preventing myocardial
siderosis, but less effective in removing hepatocellular
Cardiac iron in thalassemia with DFX, DFP and DFO
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Figure 3. Estimated MRI LIC (mg/g dw) in the groups treated with
deferiprone, desferrioxamine and deferasirox. There were significant
differences among groups (P=0.004). Post hoc analysis showed a
significantly lower LIC in the group treated with desferrioxamine ver-
sus the group treated with deferiprone and the group treated with
deferasirox. Each box shows the median, quartiles, and extreme val-
ues within the category.
Figure 4. Mean serum ferritin in the groups treated with deferiprone,
desferrioxamine and deferasirox. There were significant differences
among groups (P=0.002). Post hoc analysis showed a significantly
higher mean ferritin value in the group treated with deferasirox ver-
sus the group treated with desferrioxamine. Each box shows the
median, quartiles, and extreme values within the category. 
Table 2. Comparison of MRI data (heart and liver iron, and biventricular function parameters) among the three different groups of chelation treat-
ment.
                                                                                      Deferiprone group        Desferrioxamine group            Deferasirox group                  P
                                                                                               (n=42)                              (n=89)                                  (n=24)
Global heart T2* (ms)                                                                            34±11                                      27±11                                           21±12                              0.0001
Mid-ventricular septum T2* (ms)                                                       36±13                                      29±14                                           20±12                              0.0001
N. of segments with normal T2* (>20ms)                                         11±4                                         9±5                                               5±5                                0.0001
Liver T2* (ms)                                                                                           6±6                                         10±9                                              5±5                                 0.004
Liver iron concentration (mg/g dw)                                                   11±11                                        7±8                                             12±10                               0.004
Left ventricular EF (%)                                                                           64±6                                        61±7                                             59±7                                0.010
Left end-diastolic volume index (ml/m2)                                           89±16                                      90±19                                           89±21                                 NS
Left end-systolic volume index (ml/m2)                                             32±9                                       35±12                                           37±12                                 NS
Left ventricular mass index (g/m2)                                                      63±7                                       60±12                                           60±16                                 NS
Right ventricular EF (%)                                                                         63±7                                        59±8                                             60±5                                0.042
Right end-diastolic volume index (ml/m2)                                         87±16                                      88±20                                           88±21                                 NS
Right end-systolic volume index (ml/m2)                                           32±8                                       37±15                                           35±11                                 NS
EF: ejection fraction, NS: not significant. 
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iron, while the opposite appears to be true for desferriox-
amine.4,5,30 The data available in literature for the
deferasirox seem to confirm a good action on the liver, but
the data regarding the heart are so far preliminary and con-
tradictory.
The limits of our study were that it was retrospective
and non-randomized. Several biases could be present.
First, the duration of the treatment was significantly
shorter for deferasirox versus desferrioxamine and this
drug could be effective on the heart only after a longer
time of treatment, considering that cardiac iron removal
is a slow process with a clearance rate of around 1.5%
per month.11 Second, even though there was no signifi-
cant difference in the low percentage of patients who
had had previous combination therapy among the three
groups, the higher percentage in the deferiprone group
could have influenced the results. Third, the choice of a
particular regime was based on clinical grounds and on
evidence-based medicine. However, the choice based on
evidence-based medicine would have avoided the pref-
erential prescription of deferasirox in the patients with
greater iron load and at high risk for cardiac complica-
tions. In fact, at the time of the patients’ enrolment,
deferiprone had proved to be more effective than subcu-
taneous desferrioxamine for removing heart iron and in
improving survival.5,6 Thus, deferasirox was prescribed
for contradictions or non-optimal compliance to the
other chelators, or in patients preferring a more friendly
oral and once-daily chelator. Moreover, 13 patients start-
ed deferasirox because they were enrolled in clinical tri-
als and the patients with a poor response or non-compli-
ance with previously prescribed therapy were exclud-
ed.31
In conclusion, in patients treated for a minimum of 12
months at comparable levels of compliance, oral
deferiprone showed less myocardial iron burden and bet-
ter left global systolic ventricular function compared to
the patients treated with oral deferasirox or subcuta-
neous desferrioxamine, suggesting greater efficacy in
removing or preventing cardiac iron, with a concordant
positive effect on heart function. Conversely, desferriox-
amine appeared to be more effective in removing or pre-
venting iron deposition in the liver. However, well
designed, prospective and randomized comparative clin-
ical trials are clearly necessary, as difficult as they may be
to manage, in order to prescribe the most appropriate
chelator (or a combination thereof) for the individual tha-
lassemia major patient.
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